Zosano Pharma (ZSAN) Misses Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Zosano Pharma Reports Third Quarter 2015 Financial Results
November 9, 2015 4:01 PM ESTFREMONT, Calif., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ: ZSAN), a clinical-stage specialty pharmaceutical company, today announced financial results for the three months ended September 30, 2015.
We had a very eventful third quarter with updates on all programs. We are particularly pleased with our progress in building the depth and breadth of our organization and our clinical development advancements, said Vikram Lamba, Zosanos Chief Executive Officer. With the successful completion of our Phase 2 clinical trial on ZP-Glucagon with efficacy data demonstrating the patchs rapid onset of action and positive Phase 1 clinical trial data on... More
